Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.65 |
| ▸ | HTR2C | P28335 | 1/20 | 0.65 |
| ▸ | TAAR1 | Q96RJ0 | 8/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | NOS1 | P29475 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 3/20 | 0.45 |
| ▸ | KIF11 | P52732 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30289727 | 1.00 | HTR6 (0.65) | HTR6HTR2CTAAR1DRD2DRD1 | |
| SCHEMBL30430588 | 0.83 | PNMT (0.48) | HTR6HTR2CNOS1SMN1; SMN2LOXL2 | |
| SCHEMBL7050271 | 0.83 | PNMT (0.48) | HTR6HTR2CNOS1SMN1; SMN2LOXL2 | |
| SCHEMBL10409331 | 0.83 | HTR6 (0.69) | HTR6HTR2CTAAR1DRD2DRD1 | |
| Hydrochloric Acid SCHEMBL4935448 | 0.82 | PNMT (0.47) | HTR6HTR2CNOS1SMN1; SMN2LOXL2 | |
| SCHEMBL10061751 | 0.82 | HTR2C (0.43) | HTR6HTR2CDRD2DRD1KIF11 | |
| SCHEMBL7493101 | 0.80 | HTR2C (0.42) | HTR6HTR2CSMN1; SMN2 | |
| SCHEMBL28041624 | 0.80 | TDP1 (0.46) | HTR6HTR2CTAAR1SMN1; SMN2 | |
| SCHEMBL5180784 | 0.80 | MAPT (0.43) | HTR6HTR2CSMN1; SMN2CYP2D6 | |
| SCHEMBL5181352 | 0.80 | HTR2C (0.42) | HTR6HTR2CSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3483149-B1 | BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | YUHAN CORP (KR) | 2021-01-13 | — | — | EP | disclosed |
| US-10383859-B2 | Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same | YUHAN CORPORATION (KR) | 2019-08-20 | — | — | US | disclosed |
| US-20190142809-A1 | Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same | YUHAN CORPORATION (KR) | 2019-05-16 | — | — | US | disclosed |
| EP-3483149-A1 | BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | Yuhan Corporation (KR) | 2019-05-15 | — | — | EP | disclosed |
| US-6812228-B2 | TREATMENT OF PROGRESSIVE NEURODEGENERATIVE MOVEMENT DISORDERS CHARACTERIZED BY HYPOKINESIA, TREMOR, AND MUSCULAR RIGIDITY | WARNER-LAMBERT COMPANY | 2004-11-02 | — | — | US | disclosed |
| EP-1282625-B1 | BENZOXAZINES FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | WARNER LAMBERT CO (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20030220335-A1 | Benzoxazines for use in the treatment of parkinson's disease | WARNER-LAMBERT COMPANY | 2003-11-27 | — | — | US | disclosed |
| EP-1282625-A1 | BENZOXAZINES FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | WARNER-LAMBERT COMPANY (US) | 2003-02-12 | — | — | EP | disclosed |
| WO-2001085734-A1 | BENZOXAZINES FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | WARNER-LAMBERT COMPANY (US) | 2001-11-15 | — | — | WO | disclosed |
| EP-0244088-A2 | 1-Phenyl-3-benzazepine compounds and medicaments containing these compounds for treating gastrointestinal motility disorders | SMITHKLINE BEECHAM CORPORATION (US) | 1987-11-04 | — | — | EP | disclosed |
| US-4419367-A | METHYLTHIO-OR METHOXYPHENETHYLAMINE, SEX | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1983-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190142809-A1 | Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same | ILK, SBDS, BDKRB1 | HTR6 4218/4885HTR2C 4702/4885TAAR1 3745/4885 |
| US-10383859-B2 | Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same | ILK, SBDS, BDKRB1 | HTR6 4218/4885HTR2C 4702/4885TAAR1 3745/4885 |
| US-20030220335-A1 | Benzoxazines for use in the treatment of parkinson's disease | PARK7, HAX1, SNCA | HTR6 33/4885HTR2C 14/4885TAAR1 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.